| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2007.11.7812 |
| P698 | PubMed publication ID | 17704414 |
| P2093 | author name string | Robert Allen | |
| Richard M Goldberg | |||
| Bert H O'Neil | |||
| Dominic T Moore | |||
| Jordan D Berlin | |||
| Thomas E Stinchcombe | |||
| David R Spigel | |||
| P433 | issue | 24 | |
| P921 | main subject | cetuximab | Q420296 |
| P304 | page(s) | 3644-3648 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history | |
| P478 | volume | 25 |
| Q41918758 | A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer |
| Q37045500 | A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drug-specific IgE on basophils |
| Q30415060 | A peculiar cause of anaphylaxis: no more steak? The journey to discovery of a newly recognized allergy to galactose-alpha-1,3-galactose found in mammalian meat |
| Q36206894 | A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer |
| Q35032299 | A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions |
| Q33983656 | Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer |
| Q24599525 | Allergenicity of carbohydrates and their role in anaphylactic events |
| Q92006279 | Alpha-gal allergy after a tick bite in Austria |
| Q36907279 | Alternate dosing of cetuximab for patients with metastatic colorectal cancer |
| Q33924413 | Amblyomma sculptum tick saliva: α-Gal identification, antibody response and possible association with red meat allergy in Brazil |
| Q21245667 | Anaphylactic reactions to oligosaccharides in red meat: a syndrome in evolution |
| Q30300243 | Anaphylaxis to the carbohydrate side chain alpha-gal |
| Q35556806 | Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis |
| Q38947051 | Assessment of cetuximab-induced infusion reactions and administration rechallenge at an academic medical center |
| Q38944242 | Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid |
| Q36371601 | Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck |
| Q37378581 | Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer |
| Q41727136 | Cancer research meets tick vectors for infectious diseases |
| Q40745872 | Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma |
| Q42758064 | Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test |
| Q30441575 | Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose |
| Q26773052 | Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs |
| Q33932525 | Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab |
| Q37092129 | Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly. |
| Q38718745 | Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma |
| Q103836798 | Cracking the meat-allergy mystery with the tick-bite link |
| Q37123705 | Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer |
| Q30279084 | Delayed Anaphylaxis Involving IgE to Galactose-alpha-1,3-galactose |
| Q26775972 | Delayed anaphylaxis to alpha-gal, an oligosaccharide in mammalian meat |
| Q26995957 | Delayed anaphylaxis to red meat in patients with IgE specific for galactose alpha-1,3-galactose (alpha-gal). |
| Q30405517 | Delayed anaphylaxis to red meat masquerading as idiopathic anaphylaxis |
| Q30427410 | Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose |
| Q30384427 | Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose |
| Q38859163 | Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies |
| Q90378621 | Diagnosis and Management of Patients with the α-Gal Syndrome |
| Q54639091 | Different patterns of toxicity after sequential administration of two anti-EGFR monoclonal antibodies |
| Q30408267 | Drug allergens and food--the cetuximab and galactose-α-1,3-galactose story |
| Q30423537 | Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer |
| Q30048911 | Efficacy of Cetuximab in the Treatment of Menetrier's Disease |
| Q30409225 | Emerging antigens involved in allergic responses |
| Q64885733 | Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma. |
| Q36445108 | Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis |
| Q42711983 | Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis |
| Q30274707 | Galactose-α-1,3-Galactose: Atypical Food Allergen or Model IgE Hypersensitivity? |
| Q30413582 | Galactose-α-1,3-galactose and delayed anaphylaxis, angioedema, and urticaria in children |
| Q34070944 | Immunogenicity of panitumumab in combination chemotherapy clinical trials |
| Q59132146 | Improving Immunotherapy Through Glycodesign |
| Q43090496 | Integrating anti-EGFR therapies in metastatic colorectal cancer |
| Q37081427 | Integrating biologically targeted therapy in head and neck squamous cell carcinomas |
| Q36838995 | Nanomedicine in chemoradiation. |
| Q47117802 | New trends in anaphylaxis |
| Q39167489 | Optical Surgical Navigation for Precision in Tumor Resections |
| Q38167675 | Palliative treatment of metastatic colorectal cancer: what is the optimal approach? |
| Q33563293 | Patient considerations in metastatic colorectal cancer - role of panitumumab |
| Q37798002 | Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab |
| Q35445125 | Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma |
| Q37771250 | Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. |
| Q43167557 | Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication |
| Q46663093 | Reply to Retrospective evaluation of cetuximab-related adverse events from claims databases—methodological concerns |
| Q42245331 | Retrospective analysis of premedication, glucocorticosteroids, and H1-antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q34036360 | Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck |
| Q61810996 | Role and Mechanism of Galactose-Alpha-1,3-Galactose in the Elicitation of Delayed Anaphylactic Reactions to Red Meat |
| Q37495579 | Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience |
| Q42044313 | Second- and third-line treatment options for unresectable metastatic colorectal cancer. |
| Q48314560 | Seizure activity during cetuximab infusion in a patient with metastatic colorectal cancer. |
| Q42905909 | Successful Treatment with the Fully Human Antibody Panitumumab after a Severe Infusion Reaction with Cetuximab |
| Q31048123 | Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer |
| Q36145430 | TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer |
| Q46988997 | TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck |
| Q92747984 | Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer |
| Q33761180 | Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab |
| Q37290648 | Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. |
| Q27023451 | The alpha-gal story: lessons learned from connecting the dots |
| Q34622547 | The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer |
| Q33865354 | The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist. |
| Q92380931 | The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characterist |
| Q28647805 | The project data sphere initiative: accelerating cancer research by sharing data |
| Q24604244 | The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose |
| Q104111202 | The role of IgE specific for galactose-α-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis |
| Q37322050 | The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. |
| Q26863332 | Tick bites and red meat allergy |
| Q38344918 | Tick-induced allergies: mammalian meat allergy, tick anaphylaxis and their significance |
| Q37427386 | Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer |
| Q37218978 | Treatment of recurrent metastatic head and neck cancer: focus on cetuximab |
| Q39910176 | Using the galactose-α-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab |
| Q51469542 | Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab. |
| Q35855226 | [(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study |
| Q64905539 | [Biologics in Rhinology - Forthcoming Personalized Concepts: the Future Starts Today]. |
| Q50511429 | [Delayed appearance of symptoms in immediate hypersensitivity: type I sensitization to galactose-α-1,3-galactose]. |
| Q87240684 | [Individualized, personalized and stratified medicine: a challenge for allergology in ENT?] |
| Q85719022 | [Urticaria. Sometimes IgE-mediated?] |
Search more.